Depostat

designed to reduce the risk of metastatic spread in endometrial carcinoma

Pre-operatively Depostat
exerts a strong anti-mitotic effect on endometrial tissue.
reduces the friability of the tumour.
may prevent tumour emboli from becoming established metastases.

Post-operatively Depostat
inhibits through its strong anti-mitotic properties any metastatic spread which has already occurred.
can be used synergistically with cytotoxic agents.
may improve the quality of life of those patients with inoperable conditions.

Depostat
does not impair adrenal function, and side-effects are rare.

Depostat
another step forward in the treatment of cancer